SCHEMBL368973

SCHEMBL368973

C=C(O)Cc1ccc(O)c(O)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 6/20 0.63
MAPT P10636 6/20 0.63
HIF1A Q16665 4/20 0.63
HSD17B10 Q99714 4/20 0.63
TDP1 Q9NUW8 4/20 0.63
GAA P10253 3/20 0.63
THPO P40225 3/20 0.63
LMNA P02545 3/20 0.63
HPGD P15428 3/20 0.63
BLM P54132 3/20 0.63
PMP22 Q01453 3/20 0.63
APEX1 P27695 2/20 0.63
POLB P06746 2/20 0.63
NFKB1 P19838 2/20 0.63
RGS12 O14924 1/20 0.63
TSHR P16473 1/20 0.63
GNAI1 P63096 1/20 0.63
CA1 P00915 1/20 0.56
CA2 P00918 1/20 0.56
CA4 P22748 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8964689 0.82 KDM4E (0.57) KDM4EMAPTHIF1AHSD17B10TDP1
SCHEMBL9750653 0.80 ALOX15 (0.56) KDM4EMAPTHIF1AHSD17B10TDP1
SCHEMBL29457181 0.80 ALOX15 (0.56) KDM4EMAPTHIF1AHSD17B10TDP1
SCHEMBL19199480 0.78 ALOX15 (0.59) KDM4EMAPTHIF1AHSD17B10TDP1
3,4-Dihydroxyphenylacetic Acid SCHEMBL29382155 0.77 GAA (1.00) KDM4EMAPTHIF1AHSD17B10TDP1
3,4-Dihydroxyphenylacetic Acid SCHEMBL36348 0.77 GAA (1.00) KDM4EMAPTHIF1AHSD17B10TDP1
3,4-Dihydroxyphenylacetic Acid SCHEMBL8214147 0.76 GAA (0.96) KDM4EMAPTHIF1AHSD17B10TDP1
3,4-Dihydroxyphenylacetic Acid SCHEMBL8214151 0.76 GAA (0.96) KDM4EMAPTHIF1AHSD17B10TDP1
SCHEMBL22982989 0.74 KDM4E (0.72) KDM4EMAPTHIF1AHSD17B10TDP1
SCHEMBL10414022 0.74 TRPA1 (0.60) KDM4EMAPTHIF1AHSD17B10TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012006783-A1 PROCESS FOR PRODUCTION OF HYDROXYTYROSOL USING ORGANOMETALLIC COMPOUNDS LONZA LTD (CH) 2012-01-19 WO claimed
CN-103080056-A Method for preparing hydroxytyrosol by using organic metal compound LONZA AG 2013-05-01 CN disclosed
WO-2012006783-A1 PROCESS FOR PRODUCTION OF HYDROXYTYROSOL USING ORGANOMETALLIC COMPOUNDS LONZA LTD (CH) 2012-01-19 WO disclosed
WO-2012006783-A1 PROCESS FOR PRODUCTION OF HYDROXYTYROSOL USING ORGANOMETALLIC COMPOUNDS LONZA LTD (CH) 2012-01-19 WO disclosed
US-20110218158-A1 DNA CYTOSINE DEAMINASE INHIBITORS REGENTS OF THE UNIVERSITY OF MINNESOTA 2011-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110218158-A1 DNA CYTOSINE DEAMINASE INHIBITORS DCTD, APOBEC3A, UNG KDM4E 810/4885MAPT 4260/4885HIF1A 1753/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.